2022
How I Manage Transplant Ineligible Patients with Myelodysplastic Neoplasms
Gurnari C, Xie Z, Zeidan A. How I Manage Transplant Ineligible Patients with Myelodysplastic Neoplasms. Clinical Hematology International 2022, 5: 8-20. PMID: 36574201, PMCID: PMC10063738, DOI: 10.1007/s44228-022-00024-4.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsMyelodysplastic syndromeMyelodysplastic neoplasmsInternational Prognostic Scoring SystemHematopoietic stem cell transplantManagement of cytopeniasNon-transplant treatmentTransplant-ineligible patientsBone marrow dysplasiaAvailable therapeutic optionsMinority of patientsNew investigational agentsPrognostic scoring systemStem cell transplantMain clinical problemLow-risk groupHigh-risk casesAcute myeloid leukemiaIneligible patientsMarrow dysplasiaCell transplantInvestigational agentsTherapeutic optionsClinical managementCurative approachMyeloid leukemia
2019
Epidemiology of acute myeloid leukemia: Recent progress and enduring challenges
Shallis RM, Wang R, Davidoff A, Ma X, Zeidan AM. Epidemiology of acute myeloid leukemia: Recent progress and enduring challenges. Blood Reviews 2019, 36: 70-87. PMID: 31101526, DOI: 10.1016/j.blre.2019.04.005.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsAcute myeloid leukemiaPatient outcomesMyeloid leukemiaAllogeneic stem cell transplantationEtiology of AMLMinority of patientsStem cell transplantationAge-adjusted incidenceMost older individualsMyeloid progenitor cellsIntensive chemotherapyActive therapyClear etiologyOlder patientsRefractory diseaseSupportive careCurative therapyMedian agePoor prognosisShorter survivalCell transplantationDisease characteristicsEnvironmental DNA-damaging agentsMalignant disordersTherapeutic advances
2016
The Use of Hypomethylating Agents (HMAs) in Patients with Relapsed and Refractory Acute Myeloid Leukemia (RR-AML): Clinical Outcomes and Their Predictors in a Large International Patient Cohort
Stahl M, Podoltsev N, DeVeaux M, Perreault S, Itzykson R, Ritchie E, Sekeres M, Fathi A, Komrokji R, Bhatt V, Al-Kali A, Cluzeau T, Santini V, Brunner A, Roboz G, Fenaux P, Litzow M, Vey N, Verma V, Germing U, Fernández P, Zelterman D, Kim T, Prebet T, Gore S, Zeidan A. The Use of Hypomethylating Agents (HMAs) in Patients with Relapsed and Refractory Acute Myeloid Leukemia (RR-AML): Clinical Outcomes and Their Predictors in a Large International Patient Cohort. Blood 2016, 128: 1063. DOI: 10.1182/blood.v128.22.1063.1063.Peer-Reviewed Original ResearchMultivariable logistic regression modelRR-AMLMinority of patientsOverall survivalPrior linesHypomethylating agentHMA therapyMedian numberLogistic regression modelsChromosome 7 abnormalitiesStable diseaseBlast percentageHematologic improvementProgressive diseaseHazard ratioClinical outcomesSpeakers bureauMultivariable Cox proportional hazards modelsPeripheral blood blast percentageRefractory acute myeloid leukemiaAllogeneic stem cell transplantationInternational Working Group criteriaWhite blood cell countCox proportional hazards modelBM blast percentage